CUMYL-PeGACLONE (SGT-151) is primarily used in research settings to study its effects on the endocannabinoid system. It acts as a potent agonist at CB1 receptors, making it valuable for investigating cannabinoid receptor signaling and related physiological processes. Researchers utilize it to explore potential therapeutic applications, such as pain management, neuroprotection, and modulation of appetite. Additionally, its unique chemical structure aids in understanding the structure-activity relationship of synthetic cannabinoids, contributing to the development of novel compounds with targeted effects. However, due to its psychoactive properties, it is strictly controlled and not approved for medical or recreational use.